Overview

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Status:
Active, not recruiting
Trial end date:
2026-08-20
Target enrollment:
Participant gender:
Summary
To evaluate the safety and preliminary efficacy of acalabrutinib in combination with obinutuzumab in 4 separate cohorts of patients.
Phase:
Phase 1
Details
Lead Sponsor:
Acerta Pharma BV
Treatments:
Acalabrutinib
Obinutuzumab
Rituximab
Venetoclax